Analysis
Is compounded semaglutide or tirzepatide legal in 2026?
Compounding can be lawful under specific conditions, but shortage-era permission is not a blanket rule. Understand FDA's 503A and 503B restrictions in 2026.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
Yes, but under narrower conditions than during the shortages: as of October 9, 2026, a 503A pharmacy may compound for an individual patient under the documented significant-difference exception, while routine copies of available approved products remain restricted. All other applicable conditions still matter, and 503B outsourcing facilities have separate copying and bulk-ingredient rules; a prescription alone does not establish compliance.
Sources checked October 9, 2026. This article reports FDA’s rules and explanations. It does not decide a particular seller’s compliance, cover every state’s law or resolve patent rights.
Why the answer is conditional
“Is it legal?” often combines several questions. Is the pharmacy properly licensed? Is it working under the 503A or 503B framework? Does the prescription meet restrictions on copying approved drugs? Can the pharmacy dispense into your state? These questions cannot be answered from a telehealth brand’s presence online.
Federal compounding provisions describe conditions for exemptions from particular drug requirements. Those exemptions are not product approvals. FDA says compounded drugs are not FDA-approved, while its compounding framework distinguishes state-licensed pharmacies and physicians from registered outsourcing facilities. FDA compounding questions and answers
The useful approach is to identify which conditions apply to the actual prescription and compounder. A company’s general assurance that its product is “personalized” does not supply that information. Neither does a directory listing, a favorable review or a familiar ingredient name.
What happened to the shortage exception?
FDA reaffirmed that the tirzepatide injection shortage was resolved on December 19, 2024, and determined that the semaglutide injection shortage was resolved on February 21, 2025. Its subsequent updates describe the end of temporary enforcement periods linked to those shortages. FDA’s shortage-policy timeline
Those periods do not provide continuing blanket permission in 2026. FDA’s April 1, 2026 clarification states that neither substance appeared on its shortage or 503B bulks lists at that time. We are reporting that dated statement, not claiming a separate live shortage-database search.
This is why an old shortage announcement is insufficient support for a current offer. It may explain how the market developed, but it does not establish today’s conditions. FDA also distinguishes local supply disruptions from a national shortage determination. Being unable to find a product at one pharmacy does not itself recreate the shortage-related framework.
What can a 503A pharmacy do?
FDA’s April clarification describes 503A compounding for an individual patient based on a prescription, with restrictions on regularly making, or making in inordinate amounts, products that are essentially copies of commercially available drugs. It also describes a prescriber’s documented determination that a formulation change produces a significant difference for an identified patient. FDA’s April 2026 clarification
The distinction is patient-specific. It is not simply a choice between two advertising categories called “standard” and “personalized.” FDA’s 503A guidance explains the documentation surrounding the change and says a lower price alone does not establish the significant difference. The guidance describes FDA’s thinking and enforcement policies; it should not be mistaken for a seller-specific legal opinion. FDA’s guidance on essentially copied products
Readers can ask a prescriber or pharmacy which framework applies and what documentation supports the prescription. That is different from making their own medical determination that a customized formulation is needed. This article does not provide a formula for obtaining an exception or declare that a particular company’s prescriptions qualify.
Does adding B12 make it lawful?
Not automatically. FDA’s clarification gives semaglutide with B12 as an example that can still be considered essentially a copy under the agency’s ingredient, strength and administration-route analysis. Adding another ingredient does not, by itself, settle the copying restriction. FDA’s additive example
The question is therefore more precise than “Does it contain a vitamin?” An additive identifies a formulation detail; the applicable rules and documented patient-specific determination are separate matters. The label also does not establish an added ingredient’s clinical benefit.
FDA’s September 18, 2026 warning letter to Empower Pharmacy discussed semaglutide/cyanocobalamin and tirzepatide/niacinamide products. The agency questioned repeated significant-difference statements and prescriber menu options, alongside production volume. This is evidence of FDA’s stated concerns about that facility, not a court judgment or a ruling that every additive-containing prescription is unlawful. FDA’s warning letter
Is there a four-prescription loophole?
FDA describes an enforcement policy concerning the 503A regular-or-inordinate copying restriction when a compounder fills four or fewer prescriptions for the relevant compounded drug product in a calendar month. That is not categorical legal permission or a waiver of every other condition. FDA’s 503A guidance
This distinction matters when a seller presents a small-volume policy as proof of overall legality. A policy about whether FDA intends to take action over one restriction does not answer licensing, ingredient, prescription or other requirements. It also does not establish that a seller’s actual activity falls within the policy.
Why 503B has a different answer
Outsourcing facilities have their own conditions. For compounding from bulk drug substances, FDA describes eligibility through the 503B bulks list or a qualifying shortage-list status at compounding, distribution and dispensing. A patient-specific 503A determination does not substitute for these separate 503B bulk-ingredient rules. FDA’s 503B bulk-substance explanation
On April 30, 2026, FDA announced a proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. That announcement described a proposal; this article does not establish the later final status. Do not treat an announcement of proposed action as an already effective final decision. FDA proposal announcement
What should you verify before relying on an offer?
Request the pharmacy’s exact identity and ask which compounding category it uses. Check the relevant licensing record through FDA’s state-board directory. For a claimed outsourcing facility, consult FDA’s registration table, including its inspection and action information. These are identity and oversight checks, not a guarantee of compliance or a clinical endorsement.
Keep cost comparisons separate from that investigation. Our semaglutide and tirzepatide tables report reviewed offers and payment conditions. They do not determine whether every prescription sold by a listed company satisfies the law.
The bottom line: lawful compounding remains a conditional framework, not a universal green light. Use current regulatory sources and actual pharmacy documentation, rather than relying on old shortage headlines or a seller’s shorthand description.